Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 11 September 2012 | By Alexander Gaffney, RAC
When does a cosmetic product become a drug? When it's marketed as having advanced features that alter the body's cellular state, explained the US Food and Drug Administration (FDA) in a warning letter sent 11 September 2012 to Lancôme USA, a subsidiary of cosmetics manufacturer L'Oreal.
The letter references a number of products marketed by Lancôme, many of which claim to promote a more youthful look and go by names like, "Génifique Cream Serum Youth Activating Cream Serum" and contain modifiers such as "Precious Cells Advanced Regenerating and Reconstructing Eye Cream."
In its warning letter, FDA said the products' claims, contained on Lancôme's website, make claims indicating that they affect the function and structure of the human body, which would make them a drug as defined by the Federal Food, Drug and Cosmetic Act.
Among the claims identified by FDA as allegedly being improper include:
Regulators demanded that Lancôme remove the marketing claims from its website, but the company has not yet complied with FDA's orders.
Further, some of the suspect claims appear on numerous products marketed by Lancôme. For instance, the entire product line of Génifique products uses the claim that the products, "Boosts the activity of genes."
Other claims on the website, such as one that claims to, "Support cellular communication," could also to fall into FDA's definition of drug products, though they were not listed specifically in FDA's warning letter. The agency's standard qualification-"This letter is not an all-inclusive statement of violations associated with your products or their labeling"-was also contained within the letter, and FDA said it had not attempted to find all violations present on the company's website.
The company has until 21 September 2012 to respond to the agency, after which time its products may be subject to an injunction and seizure by the agency.
An email requesting comment from L'Oreal was not returned by the time of this article's publication.
Tags: Makeup, Lancome, L'Oreal, warning letter, Cosmetic, Latest News, marketing, claims
Regulatory Focus newsletters
All the biggest regulatory news and happenings.